Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib in FLT3-ITD Positive Relapsed/Refractory AML
NCT01565668Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2012
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd.. Started Apr 2012; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01565668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01565668.